Trials / Completed
CompletedNCT00719953
Study to Assess the Efficacy of Cognitex
A Single-Center, Open-label Study to Assess the Efficacy of Cognitex in Elderly Subjects With Memory Impairment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Tel-Aviv Sourasky Medical Center · Other Government
- Sex
- All
- Age
- 60 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
A Single-Center, Open Label Study to Assess the Efficacy of Cognitex in Elderly Subjects with Memory Impairment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Cognitex | Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2009-03-01
- Completion
- 2009-08-01
- First posted
- 2008-07-22
- Last updated
- 2010-04-20
- Results posted
- 2010-02-04
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00719953. Inclusion in this directory is not an endorsement.